Author

S. Lederman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Organism:human· 1 Organism:non-human primate· 1 Organism:rat· 1

Frequent Co-Authors

F. Nasar· 3 shared S. Bavari· 3 shared A. Macaluso· 2 shared B. Daugherty· 2 shared M. Awasthi· 2 shared R. S. Noyce· 2 shared S. J. Goebel· 2 shared A. Cregger· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

F. Nasar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Recombinant chimeric Horsepox Virus (TNX-801) is attenuated relative to Vaccinia Virus Strains in Human Primary Cell Lines and in Immunocompromised Mice

S. Trefry, C. Raney, A. Cregger, N. Martinez, B. Layton, R. Enamorado, D. Gohegan, T. Moulaei, N. Ziolkowska, S. Goebel, S. Lederman, S. Bavari, F. Nasar

This study compares the attenuation of TNX-801, a recombinant chimeric Horsepox virus, to VACV-based vaccines in cell lines and mice, showing TNX-801 is significantly more attenuated.

bioRxiv · Oct 25, 2023 · PreprintMicrobiology

Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, Against SARS-CoV-2 Challenge in Nonhuman Primates

M. Awasthi, A. Macaluso, D. Myscofski, J. Prigge, F. Koide, R. S. Noyce, S. Fogarty, H. Stillwell, S. J. Goebel, B. Daugherty, F. Nasar, S. Bavari, S. Lederman

This study evaluates the immunogenicity and efficacy of TNX-1800, a poxvirus vaccine expressing SARS-CoV-2 spike protein, in nonhuman primates challenged with SARS-CoV-2.

bioRxiv · Sep 19, 2023Immunology

Immunogenicity and tolerability of a SARS-CoV-2 TNX-1800, a live recombinant poxvirus vaccine candidate, in Syrian Hamsters and New Zealand White Rabbits.

M. Awasthi, A. Macaluso, S. J. Goebel, E. Luea, R. S. Noyce, F. Nasar, B. Daugherty, S. Bavari, S. Lederman

This study evaluates the immunogenicity and tolerability of the SARS-CoV-2 vaccine TNX-1800 in hamsters and rabbits, finding it well-tolerated with undetectable viral load after 28 days.

bioRxiv · Sep 6, 2023Immunology